Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 03:20 p.m. PT. The event will take place in Rancho Palos Verdes, CA. A live webcast will be available on the Company’s website, with an archived replay for 90 days. Repare specializes in cancer therapies using its SNIPRx® platform, focusing on genomic instability and DNA damage repair, and is currently developed leading products like camonsertib (RP-3500) and RP-6306.
Repare Therapeutics has entered a worldwide license and collaboration agreement with Roche for the development of camonsertib (RP-3500), a selective ATR inhibitor targeting specific tumors. Repare will receive a
Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in the virtual 2022 Guggenheim Synthetic Lethality Day on May 16, 2022, at 9:00 a.m. ET. Senior management will engage in a fireside chat, providing insights into their precision oncology strategies. Interested parties can access a live webcast via the Investor section on their website, with an archived replay available for 90 days post-event. Repare is known for its innovative SNIPRx® platform focusing on synthetic lethality in cancer therapeutics development.
Repare Therapeutics Inc. (Nasdaq: RPTX) reported significant advancements in its RP-3500 program and showcased promising clinical data from the Phase 1/2 TRESR Trial at the 2022 AACR Annual Meeting. The trial demonstrated a 75% clinical benefit rate (CBR) in advanced ovarian cancer patients and 43% CBR across various solid tumors. Financially, the company reported cash reserves of $311.7 million but registered a net loss of $34.8 million for Q1 2022, reflecting increased R&D expenses. Repare anticipates further updates on camonsertib’s potential later in the year.
Repare Therapeutics has announced promising preclinical data that positions RP-6306, a first-in-class PKMYT1 inhibitor, as a potential treatment for CCNE1-amplified cancers. This data was published in Nature and shows significant tumor growth inhibition in vivo. Currently in Phase 1 clinical trials, RP-6306 is being studied both as a monotherapy and in combination with gemcitabine and FOLFIRI for advanced solid tumors. The SNIPRx platform played a pivotal role in identifying this novel therapeutic target, underscoring Repare's innovative capabilities.
Repare Therapeutics presented promising results for its drug
Repare Therapeutics Inc. (Nasdaq: RPTX) announced comprehensive Phase 1 monotherapy data from its ongoing Phase 1/2 TRESR trial for RP-3500, an ATR inhibitor, to be presented at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. An oral presentation is scheduled for April 11, 2022, at 3:05 PM CT, led by Dr. Timothy Yap. The company will host a conference call to discuss these findings on the same day at 6:30 PM ET. Repare aims to highlight RP-3500's therapeutic potential and ongoing development plans.
Repare Therapeutics (NASDAQ: RPTX) announced that it will present clinical data from its Phase 1/2 TRESR trial of RP-3500 at the upcoming 2022 AACR Annual Meeting in New Orleans. The oral presentation, focusing on genomic determinants of response to RP-3500 in patients with DNA damage repair mutant tumors, is scheduled for April 11, 2022. Additionally, a poster will be presented on the SNiPDx panel, aimed at detecting DNA repair gene losses in tumor samples, on April 12, 2022. Repare’s SNIPRx® platform supports its precision therapeutics development.
Repare Therapeutics Inc. announced positive findings from its Phase 1/2 TRESR clinical trial of
The company plans to share updated data from 120 patients in the first half of the year, reinforcing expectations for the therapeutic potential of
Repare Therapeutics Inc. (RPTX) reported its financial results for Q4 and full year 2021, highlighting key advancements in its precision oncology pipeline. Notable progress includes the initiation of the RP-6306 program and the RP-3500 Phase 2 trial for solid tumors. By December 31, 2021, cash reserves stood at $341.9 million, sufficient for operations through 2023. R&D expenses surged to $90 million, reflecting increased development costs. The net loss was $106.9 million, or $2.83 per share, compared to $53.4 million, or $2.66 per share in 2020.